|
Originally published In Press as doi:10.1074/jbc.M203553200 on July 11, 2002
J. Biol. Chem., Vol. 277, Issue 42, 39156-39162, October 18, 2002
Molecular Mechanisms of Pre-T Cell Receptor-induced
Survival*
Cristina
Murga §¶ and
Domingo F.
Barber§
From the Centro de Biología
Molecular, Universidad Autónoma de Madrid, Cantoblanco,
Madrid 28049, Spain and the Department of Immunology and
Oncology, Centro Nacional de Biotecnología, Universidad
Autónoma de Madrid, Cantoblanco, Madrid 28049, Spain
Received for publication, April 12, 2002, and in revised form, July 9, 2002
 |
ABSTRACT |
En route to maturing as T cell
receptor (TCR)  -expressing cells, the development of thymocytes
is contingent on expression of a pre-TCR complex comprising a TCR
chain paired with a surrogate TCR chain, pre-T (pT ). The
pre-TCR has been proposed to promote cell survival, proliferation,
differentiation, and lineage commitment. However, the precise molecular
mechanisms governing this variety of effects remain elusive. Here, we
present a cellular system designed to biochemically dissect signals
elicited upon pre-TCR expression. Using the T cell line 4G4 stably
transfected with one of the two known pT isoforms or selective pT
deletion mutants and TCR , we were able to observe that expression of
a functional pre-TCR complex is sufficient to control the levels of
surface Fas protein, the stimulation of mitogen-activated and
stress-regulated kinases, and the activation status of the p53
antioncogene. We demonstrate that this regulation has a major impact on
the expression of important regulators of apoptosis, such as Bcl-2
family members, and the cell cycle, such as p21WAF.
Furthermore, we show here that cells expressing a functional pre-TCR
are more resistant to different types of DNA damage-induced apoptosis
and that these effects are contingent on an intact cytoplasmic tail of
pT . We finally propose that the presence of a functional pre-TCR
complex triggers many intracellular pathways capable of driving and
ensuring thymocyte survival in the presence of DNA damage.
 |
INTRODUCTION |
Development of immature thymocytes is contingent on passage
through at least two major checkpoints: positive selection mediated by
interactions of TCR with proteins of the major
histocompatibility complex, and the -selection point mediated by
major histocompatibility complex-independent signaling through the
pre-TCR1 (1-5). The most
immature thymocytes are double negative (DN) for CD4 and CD8 expression
and progress through four subsets defined by CD44 and CD25 expression:
DN I (CD25 CD44+), DN II (CD25+
CD44+), DN III (CD25+ CD44lo), and
DN IV (CD25loCD44lo) (6). From these arise
CD25loCD44lo CD3lo
CD4 CD8+ immature single positive cells that
develop into cells double positive (DP) for CD4 and CD8 expression (7),
from which mature TCR (+) thymocytes are selected. The major
changes associated with TCR gene rearrangement occur at the
transition from DN III to DN IV cells, precisely when the pre-TCR is
expressed. However, whether the presence of pre-TCR is sufficient to
induce the concomitant occurrence of these many events remains still an
unresolved matter.
Like TCR , the pre-TCR is a multicomponent signaling complex
comprising a TCR chain paired with at least one of two isoforms of a
pT molecule both associated with CD3 chains, specifically ,
either or , and to some extent (8-13). The pre-TCR
spontaneously clusters and associates with signaling molecules such as
p56lck, CD3 molecules, and zap-70 via sequestration in lipid rafts even in the absence of any extracellular ligand (14), consistent with the
idea that the main role for the pre-TCR is to facilitate pairing with
the CD3 complex. However, unlike TCR , the pre-TCR has an
additionally extended cytoplasmic tail encoded by the pT gene.
Within the tail two proline-rich motifs can be identified by sequence
similarity to motifs in the cytoplasmic tail of human CD2 that mediate
binding to CD2BP2, an adaptor molecule involved in intracellular
signaling (8, 16). Heretofore, the importance of the intracytoplasmic
region of the pre-TCR has been uncertain, but very recently the
expression of pT mutants in retrovirally transduced T cell
precursors and cell lines showed that the pT cytoplasmic tail, in
particular the proline-rich domain, plays a crucial role in pre-TCR
signal transduction (17).
Based on the analysis of cells on either side of the DN III to DN IV
transition, the pre-TCR has been hypothesized to regulate thymocyte
survival, proliferation, differentiation, and lineage commitment
(18-21). Several classes of molecules implicated in the regulation of
apoptosis were noted to change as DN III cells moved on to become DN IV
cells. First, the prototypic death receptor, Fas, shows very poor
expression in DN cells compared with the high levels found in DP
thymocytes (22). Second, as recently reported (23), changes were noted
in the DNA binding activity of NF- B, a known inhibitor of
pro-apoptotic signaling from death receptor pathways. In mice
transgenic for a luciferase gene driven by a NF B-responsive element,
luciferase activity was significantly greater in DN IV cells than in DN
III and dropped precipitously in DP cells (23). Third, apoptosis
induced by DNA damage requires an intact p53 antioncogene in thymocytes
(24) and occurs via transcriptional activation of the
cyclin-dependent kinase inhibitor p21WAF (25).
A lack of p53 in a CD3 -deficient background impairs cell death in DN
thymocytes and partially rescues the block in pre-TCR cell
differentiation caused by this pre-TCR defect (26).
The analysis of mutant mice expressing variant forms of either the
pre-TCR or of molecules putatively associated with it support the fact
that only thymocytes that succeed in generating a functional TCR
chain selectively survive through the transition from DN III to DN IV.
However, despite the elegance of these in vivo experiments, there is little direct evidence showing a cause and effect relationship between the pre-TCR expression and its proposed anti-apoptotic function. This is of some concern because multiple regulators of
thymocyte survival and fate are expressed in vivo
(e.g. Notch and Interleukin-7), any of which may be
primarily responsible for changes observed in cells as across the DN
III to DN IV transition (27, 28). In addition, the very low levels of
expression of the pre-TCR in thymocytes make it very difficult to
detect and even more difficult to biochemically characterize this
molecule. All of these difficulties emphasize the need for additional,
complementary approaches to study pT function.
In this report we undertake one such new approach by using exogenous
expression of the pre-TCR genes to examine the influence that this
molecule exerts on some important regulators of programmed cell death
(apoptosis) and thymocyte differentiation. Here, we describe the
development and characterization of a variety of stably transfected
clones expressing different pre-TCR chains in a T cell line able to
express a functional pre-TCR complex upon transfection of the pT and
TCR chains (11). The capacity of the pre-TCR to regulate the
expression of Fas, Bcl-2 family members, and the activity of key
molecules such as p53 and stress-regulated kinases is analyzed here. We
also test in this system the effect of pre-TCR expression in the
regulation of cell death induced by DNA damage. Altogether, the results
presented in this study allow us to conclude that expression of a
complete and functional pre-TCR complex is able per se to
regulate multiple signals that bring about the inactivation of p53,
activation of mitogen-activated protein kinases/stress-activated
protein kinases, and down-regulation of pro-death gene products such as
Fas, p21, and Bax.
 |
EXPERIMENTAL PROCEDURES |
DNAs, Transfections, and Generation of Stable Clones--
4G4
cells were electroporated with DNAs encoding a TCR chain alone or
together with HA-tagged pT a and pT b
constructs and were selected in G418 (Invitrogen), as described (11).
Clones transfected with either one isoform of the pT chain alone,
without cotransfection of the TCR chain, expressed the pT
mRNA as could easily be detected by reverse transcription-PCR. However, we were unable to detect any pT protein in those selected clones either by FACS or by Western blot, thus indicating that the
pre-T chain does not form a stable protein complex when devoid of
TCR , consistent with what has been described before (29). A
truncated form of pT b, named P1P2, in which the last
cytoplasmic 16 amino acids containing two proline-rich regions were
deleted, was PCR-generated with the following primers:
5'-AATAGATCTCTACCATCAGGGGAATCT-3' (containing a BglII site)
and 5'-AATCCGCGGCTACTGGAGGTGCTGGCCCGC-3' (containing a SacII
site). The product was cloned into pGEM-T-Easy (Promega), from which it
was subcloned in frame using BglII/SacII into the expression vector pDisplay that includes an N-terminal HA tag (Invitrogen) (13).
Analysis of Transfectants for Pre-TCR Components--
Expression
of transfected proteins was analyzed by Western blot and by
intracellular flow cytometry, as described (11). For Western blots,
107 cells were collected by centrifugation and resuspended
in lysis buffer as described previously (30); subsequently the protein content of each sample was measured (DC protein assay; Bio-Rad). For
detection of pT , 600 µg of total cell lysates were
immunoprecipitated with anti-HA antibodies (12CA.5; Roche Molecular
Biochemicals). The precipitates were eluted off beads by boiling,
separated in 15% SDS-PAGE in parallel with prestained markers, and
transferred to polyvinylidene fluoride membranes (Immobilon P;
Millipore). Proteins containing a HA epitope were detected with another
anti-HA antibody (HA.11; Covance) followed by peroxidase-conjugated
secondary antibody (Cappel) and developed with a chemiluminescent
method (ECL; Amersham Biosciences). For detection of TCR , the
lysates were resolved by PAGE, transferred to polyvinylidene fluoride membranes, and directly detected with an antibody directed against the
C terminus of TCR (catalog number 1579 from Santa Cruz
Biotechnology). For intracellular flow cytometry, the cell suspensions
were fixed in 1% paraformaldehyde for 10 min, washed in
phosphate-buffered saline, and resuspended in a 0.3% saponin (Sigma)
buffer for 10 min. Further staining steps were carried out in 0.1%
saponin buffer. The antibodies used were phycoerythrin-conjugated
H57-597 and fluorescein isothiocyanate-conjugated 12CA.5. The cells
were washed in phosphate-buffered saline and analyzed immediately on a
FACS Calibur. Data analysis was performed using CellQuest.
Induction of UV-induced Apoptosis in Pre-TCR
Transfectants--
Susceptibility to apoptosis in 4G4-derived clones
was determined as follows. The cells were grown on
poly-D-lysine-treated coverslips for 1-2 days before being
subjected to UV irradiation (120 Jul/m2) as described
previously (30). The cells were then maintained in a serum-free,
G418-free medium for 6 h and fixed for 30 min in 4%
paraformaldehyde in phosphate-buffered saline. After permeabilization in 2% Triton X-100 and blocking for 1 h in 4% bovine serum
albumin in phosphate-buffered saline, the TUNEL reaction was performed using an in situ cell death detection kit (Roche Molecular
Biochemicals) following the manufacturer's instructions, except that
the labeling reaction was performed at 25 °C instead of at 37 °C.
After DAPI staining, the cells were mounted on coverslips and counted
using a Zeiss Axioplan2 fluorescence microscope. The percentage of
apoptotic cells was calculated by counting total (DAPI-stained) and
apoptotic (TUNEL-positive) cells.
Fas expression was measured by flow cytometry using the Jo-2 antibody
(22) (anti-FAS-phycoerythrin (BD-Pharmingen)) and expressed in
arbitrary units reflecting mean fluorescence intensities. All of the
data plots showed unimodal distribution of Fas expression.
Analysis of Transfectants for Stimulation of Mitogen- and
Stress-activated Kinases--
Total cell lysates were prepared, and
protein concentration was measured (DC protein assay; Bio-Rad) as
described above. Each sample (400 µg) was immunoprecipitated with
anti-JNK (BD-Pharmingen) or anti-p38 antibodies (Santa Cruz
Biotechnology). Kinase activity was assayed using, in anti-JNK
precipitates, 4 µg of glutathione S-transferase-c-Jun
(1-79). To measure the activation of p38 an antibody anti-phospho-p38
(1:1000, Cell Signaling) was used. Total kinase levels in the different
clones were assessed by Western blot analysis using anti-JNK
(BD-Pharmingen) or anti-p38 (Santa Cruz Biotechnology). As a positive
control, the clones were treated with a calcium ionophore (1 µM ionomycin; Calbiochem) and a phorbol ester (100 ngr/ml
12-O-tetradecanoylphorbol-13-acetate; Calbiochem) for p38
activation or 1 M NaCl for JNK stimulation 30 min prior to
cell lysis.
Analysis of the Effects of DNA Damage--
To measure the
response to genotoxic agents of the p53 pathway in each clone, 4G4
transfectants were grown to 106 cells/ml and then treated
with 1 µg/ml doxorubicin (Sigma) for several periods of time. A peak
in p53 phosphorylation was found to lie at 6 h of treatment fading
subsequently until undetectable after 16 h. After a 6-h treatment,
the cells were lysed as described above, and each sample was
immunoprecipitated with 1 µg of anti-p53 antibody (Ab-1; Calbiochem)
and subjected to Western blot analysis using anti-Ser(P)15
p53 (1:1000; New England Biolabs) with appropriate secondary antibodies
(1:5000; Cappel). Total p53, p21, and Bax levels in the different
clones were quantified by Western blot analysis of 60 µg of total
cell lysate using anti-p53 (Ab-3; Calbiochem), anti-p21WAF
(SX118; Pharmingen), and anti-Bax (Santa Cruz Biotechnology). To
quantify the content of Bcl-2 protein in the panel of clones, Western
blots were performed using two different anti-Bcl-2 antibodies (Santa
Cruz Biotechnology number sc-7382 and Pharmingen number 15021A). For
apoptosis studies, the cells were treated with 1 µg/ml doxorubicin
(Sigma) for 72 h previous to staining with propidium iodide
followed by FACS analysis. The percentage of dying cells was determined
by electronic gating of the sub-G1 population.
 |
RESULTS |
Characterization of Pre-TCR Transfectants--
The T cell line 4G4
(11) was used to stably express several pre-TCR constructs. Different
clones of transfectants were established by drug selection and
expression of TCR alone; TCR plus either the large
(pT a) or short (pT b) pT isoforms; and
TCR plus a mutant form of pT b (termed P1P2), in
which two CD2-like proline motifs in the cytoplasmic tail were deleted
was confirmed by Western blot (Fig. 1)
and flow cytometry (not shown). Although the levels of expression
varied slightly among different transfectant clones receiving the same cDNAs, the different gene products were readily detectable in every
case (Fig. 1 and data not shown). Thus, mutations of the pT tail did
not significantly affect expression or stability of pT or TCR in
these cells.

View larger version (59K):
[in this window]
[in a new window]
|
Fig. 1.
Analysis of the level of expression of
transfected HA-pT constructs in stably
transfected T cells. A, total cell lysates from parental 4G4
cells and from stable clones (designated with different numbers)
expressing either the TRC chain alone ( ) or in combination with
the pT b or pT a isoforms of the pre-T
( /pT b and /pT b, respectively) or a
mutant pT b ( P1P2/ ) were immunoprecipitated
(IP) with the aid of an anti-HA antibody as described under
"Experimental Procedures." The immunocomplexes were then resolved
by PAGE and detected by Western Blot (W Blot) with another
anti-HA antibody. The positions of the different HA-tagged proteins are
indicated by arrows. The relative molecular masses of the
different polypeptides results as follows: pT a = ~33
kDa; pT b = ~14.3kDa; and pT P1P2 = ~12.5
kDa. An additional background band is detected by the HA antibody that
migrates at ~15 kDa. The positions of the heavy and light chains of
immunoglobulin proteins are depicted by arrows (H
and L, respectively), as are the positions of molecular mass
markers for 46 and 31 kDa. B, expression of
transfected TCR constructs in the clones described for A.
Total cell lysates were analyzed by PAGE and Western blotted with a
monoclonal antibody. A specific band corresponding to TCR was
detected at ~37 kDa.
|
|
Functional Regulation of Fas and Apoptosis by Pre-TCR
Expression--
With the aim to determine whether the pre-TCR
expression could protect from apoptotic cell death, we developed a
system where apoptosis was induced in the various transfectant clones
upon irradiation with UV light. Interestingly, those transfectants receiving a complete set of pre-TCR components appeared more resistant to UV-induced apoptosis than those receiving either TCR alone or
cells expressing TCR plus the pT tail mutant P1P2
pT b (Fig. 2). For example,
for TCR -only transfectants, this procedure induced death in >80%
of cells, whereas in several TCR +pT transfectants, only ~20%
of cells underwent apoptosis after UV treatment.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 2.
Susceptibility to UV-induced apoptosis in
different pT -expressing clones.
A, T cell clones expressing combinations of pre-TCR complex
proteins were UV-irradiated as described under "Experimental
Procedures" and subsequently subjected to TUNEL apoptosis detection.
The apoptotic cells were quantified and expressed as percentages of the
total number of cells counted. The data are represented as the
means ± S.E. from three independent experiments. Note the reduced
number of apoptotic cells in all pT -expressing clones.
|
|
Susceptibility to this UV-induced cell death has been attributed to
ligand-independent activation of Fas in T cells (31-33), and it can
also be mediated by p53. Consistent with this data, those clones
expressing a complete pre-TCR displayed partially reduced surface Fas
expression (Fig. 3) as compared with
parental cells or cells expressing the TCR chain alone.
Significantly, pre-TCR-induced changes in Fas levels were not
measurably reduced in clones expressing the cytoplasmic tail mutant of
pT (Fig. 3), demonstrating a contribution of the pT tail both to
the regulation of surface Fas expression and to protection from
UV-induced apoptosis.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 3.
Differential expression of Fas (CD95) in T
cell clones stably transfected with pre-TCR components. The
pre-TCR-expressing clones utilized in Fig. 2 were analyzed for Fas
expression using phycoerythrin-conjugated antibody Jo-2 (BD-Pharmingen)
by FACS analysis as described under "Experimental Procedures." The
mean fluorescence intensities of unimodal expression plots were
expressed as arbitrary units on the y axis. The values are
expressed as the means ± S.E. obtained from four independent
experiments. Note the low relative expression of Fas in
pT -expressing clones.
|
|
Effects of Pre-TCR Expression on DNA Damage-mediated
Events--
The presence of double-stranded DNA breaks caused by V(D)J
recombination has been considered the source of the apoptotic response that leads to depletion of entire populations of thymocytes (24). This
critical event occurs early in the -selection checkpoint and can be
reversed by expression of a TCR chain paired with the pT gene
product. However, exactly how pre-TCR expression promotes protection
from DNA damage-induced apoptosis is still an unresolved question. In
an attempt to answer this question, we performed a set of experiments
using chemotherapeutic agents as opposed to UV irradiation to avoid any
Fas-mediated effects. Pre-TCR-expressing clones were treated with
doxorubicin, a drug known to cause severe DNA damage through inhibition
of topoisomerase II (34). Upon doxorubicin treatment, transfectants
expressing a full set of pre-TCR components displayed high levels of
protection relative to those receiving either TCR alone or cells
receiving TCR plus the pT tail mutant (Fig.
4). For example, for TCR -only transfectants the death rate was between 80 and 95% of cells, whereas
less than 30% of the TCR +pT transfectants were dead. These data
demonstrated that expression of pre-TCR is sufficient per se
to effectively protect cells from DNA damage-induced apoptosis.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 4.
Susceptibility to DNA damage-induced
apoptosis of pre-TCR transfectant T cell clones. A panel of 4G4
clones expressing different pre-TCR components were subjected
(filled bars) or not (empty bars) to doxorubicin
treatment to provoke DNA damage-induced cell death and subsequently
analyzed as described under "Experimental Procedures." The
sub-G1 population was quantified by FACS analysis using
propidium iodide staining, and the values are expressed as percentages
of the total amount of stained cells. The data are represented as the
means ± S.E. obtained from three different experiments.
|
|
It has been suggested that the pre-TCR regulates progression through
the DNA damage checkpoint characteristic of the DN to DP transition by
inactivating p53 (26). With the aim to biochemically assess whether
pre-TCR could somehow regulate p53 levels or activity, we set out to
determine whether the total levels of p53 and two well established
p53-regulated genes, namely p21WAF (35) and Bax (36), were
altered in representative clones expressing TCR alone or TCR plus
any of the pT isoforms and TCR plus P1P2 pT b.
As shown in Fig. 5A, the total
content of p21WAF or Bax protein was markedly reduced in
those clones expressing either isoform of the pT . In sharp contrast,
the total amount of a pivotal pro-survival gene product, Bcl-2, was
increased in those particular clones (Fig. 5C). Essentially
the same result was obtained using a second anti-Bcl-2 antibody
(15021A, BD-Pharmingen). The levels of p53 protein were very similar in
all clones tested, indicating that possible changes in the amount of
total p53 do not seem to be the cause of the differences observed in
p21WAF and Bax expression. Of note, clones expressing the
P1P2 mutant of the pT b plus TCR did not display
any detectable changes in p21WAF, Bcl-2, or Bax when
compared with TCR -expressing control cells. These results pointed at
the possibility that the p53 transcriptional activity, and not total
p53 levels, was somehow decreased in pT -expressing cells.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 5.
Analysis of the status of the p53 pathway in
pre-TCR-stable transfectant T cell clones. A, total
protein levels of p21WAF, p53, and Bax were quantified in
selected clones by Western blot (W Blot) of total cell
lysates (60 µg/lane) using specific antibodies as
described under "Experimental Procedures." The migration of each
protein is indicated by an arrow. Essentially the same
result was obtained in three independent experiments. B,
expression of Bcl2 protein in a panel of clones as analyzed by Western
Blot with specific anti-Bcl2 antibodies. A band was detected at ~26
kDa corresponding to Bcl2 and is indicated by an arrow. The
figure is representative of three different experiments. C,
selected transfectants were treated (+) or not ( ) with doxorubicin
for 6 h, and the amount of total protein required to normalize for
the same total levels of p53 was subjected to immunoprecipitation with
an anti-p53 antibody (Ab-1). After electrophoresis, the proteins were
transferred to a polyvinylidene fluoride membrane and blotted using an
anti-phospho-p53 (Ser15). To verify equal loading of p53,
the same membrane was stripped and subsequently reblotted using an
anti-p53 antibody as described under "Experimental Procedures." The
migration of the p53 protein is indicated by an arrow.
The autoradiograph shown is representative of three
independent experiments.
|
|
To further challenge this hypothesis, we needed to test the
functionality of the p53 protein itself. With that purpose, we took
advantage of the availability of sensitive anti-phospho-p53 antibodies
that allowed us to test the activation status of the p53 protein
in situ. In particular, phosphorylation of Ser15
in p53 has been demonstrated to increase the ability to transactivate p21WAF upon DNA damage (37) and represents a prototypical
marker for p53 activation upon DNA damage. In cells treated with
doxorubicin, an inhibitor of topoisomerase II, we could observe a clear
phosphorylation of endogenous p53 in cells expressing TCR that were
used as a control when the same total levels of p53 were loaded into
the gel (Fig. 5C). However, we detected differences in the
activation status of p53 in response to doxorubicin in the different
4G4-derived clones. The amount of phosphorylated p53 was reduced in
cells expressing pT b plus TCR as compared with cells
expressing only TCR , although this difference was even more evident
in cells expressing pT a plus TCR , where very low
levels of phosphorylated p53 could be detected (Fig. 5C). We
also noticed that transfectants expressing the P1P2
pT b mutant showed normal levels of p53 phosphorylation.
This observation highlights again the importance of the cytoplasmic
domain of the pT for certain biochemical effects of the pre-TCR and
further corroborates that expression of a functional pre-TCR protein
leads to defective phosphorylation of p53 upon DNA damage.
The Pre-TCR Controls the Activation of Stress-regulated
Kinases--
Several studies have established a very important role
for mitogen- and stress-activated kinases in the regulation of
thymocyte development and survival (38). To gain a mechanistic
understanding on how the pre-TCR might contribute to the regulation of
this type of pathway, 4G4 transfectants were examined for changes in the status of two such protein kinases, JNK and p38 . Pre-TCR transfectants showed increased basal kinase activity of JNK. Most notable was the absence of any JNK activity in transfectants expressing the tail mutant of pT plus TCR (Fig.
6); indeed, JNK activities in these
transfectants were lower than those found in cells receiving TCR
alone. By contrast, absolute levels of JNK protein were essentially the
same in all clones (Fig. 6B). We next tested the ability of the pre-TCR to modulate a mitogen-activated kinase that has also been
implicated in the regulation of thymocyte development (39, 40) namely
p38. The basal activity of p38 appears to be elevated in the
pT b-expressing cells when compared with TCR or
pT a transfectants that showed very low p38 activity
(Fig. 6A). Also in this case, deletion of intracytoplasmic
domains abolished the transduction of signals from the receptor to the
p38 kinase.

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 6.
Regulation of JNK and p38 pathways by
expression of pre-TCR components. A complete panel of stable
transfectants expressing pre-TCR components was analyzed for total
levels and activity of p38 (A) and JNK (B).
Total kinase protein levels of JNK and p38 were determined by Western
blot on 60 µg of total cell lysates as described under
"Experimental Procedures." The JNK activity was determined by
incorporation of phosphate into recombinant glutathione
S-transferase-c-Jun (1-79) (GST-cjun), a
specific JNK substrate, and p38 activation by using an anti-phospho-p38
antibody. Note the differential activation of these kinases by
expression of the various pre-T isoforms. As a positive control, the
clones were treated with a calcium ionophore (ionomycin) together with
a phorbol ester (Ca2+ + 12-O-tetradecanoylphorbol-13-acetate (TPA)) for
p38 activation or subjected to osmotic stress (1 M NaCl)
for JNK stimulation for 30 min prior to cell lysis. W Blot,
Western blot.
|
|
 |
DISCUSSION |
The selection checkpoint is a critical step in lymphocyte
development defined not by a single biochemical event but by a plethora
of varied cellular changes affecting apoptosis regulators, cell cycle
effectors, and other signaling pathways (reviewed in Ref. 41). These
include, but may not be restricted to, the down-regulation of Fas (22),
the activation of NF- B (23), the regulation of p38 (40), and the
inhibition of p53 (26). All of these changes have been shown to occur
during the time interval surrounding pre-TCR expression; however, no
direct cause and effect relationship has been demonstrated that
directly links the pre-TCR molecule with these intracellular events. To
try to clarify whether these changes are the direct consequence of the
expression of the pre-TCR molecule or simply simultaneous in time, we
have developed and characterized T cell clones stably expressing
different components of the pre-TCR complex. This system allowed us to
explore in detail the signaling cascades that this molecule is able to
launch and to measure defined biological consequences. Some of these
transfectants have been already utilized to show that NF- B
activation in stage III thymocytes is dependent on expression of
pre-TCR (23). The findings reported here that pre-TCR can be
functionally assayed in an heterologous system create the potential for
delineating the pathway from pre-TCR to downstream effectors and for
exploring the implication of defined pT domains in such effects.
In particular, the role of the cytoplasmic tail of the pT , unique
among TCR chains, has been proposed in the past (41). However,
complementation studies in pT -deficient mice have so far produced
ambiguous results (Refs. 13 and 17 and references therein) that have
lead to some controversy in the field. Only recently, a study by
Aifantis et al. (17) by expression of different pT
mutants in retrovirally transduced T cell precursors and cell lines
showed that the pT cytoplasmic tail, in particular the proline-rich
domain, plays a crucial role in pre-TCR signaling and T cell
development. In our report we progress one step further and elucidate
the molecular basis for this biological effect by demonstrating an
essential role of the pT tail in pre-TCR-mediated survival and
signaling. We also establish here that the pT tail is indeed
required for at least some of the biological functions elicited by the
pre-TCR.
Also using the cellular system described here, we were able to
challenge the influence that pre-TCR expression has in the expression
of Fas protein. In support of some involvement of Fas in DN thymocyte
development, thymocytes from severe combined immunodeficiency mice, which cannot ordinarily survive -selection, show improved DN
to DP maturation when the severe combined immunodeficiency mutation is
bred onto a Fas deficiency (42). In this regard, it is worth mentioning
that the analysis of thymocyte subsets showed that the decrease in Fas
expression observed in DN cells was attributable primarily to subsets I
and IV; Fas levels were high in DN II and DN III but showed a specific
decline on DN IV cells (22), just after the pre-TCR checkpoint. These
results argue that a selective decline in Fas levels during
-selection would be necessary for a correct DN to DP transition and
raise the possibility that the pre-TCR may somehow regulate this
phenomenon. Using the heterologous system described here, we were able
to demonstrate that there is a selective drop in the amount of Fas upon
expression of any of the two full-length pT proteins together with a
TCR chain. Furthermore, there seems to be a correlation between the
levels of Fas expressed in different pre-TCR clones and the
susceptibility of these clones to apoptosis induced by engagement of
Fas. Our observations are in full agreement with the in vivo
results mentioned above and demonstrate that there is a direct
correlation between expression of the pre-TCR and the levels of Fas and
further suggest that the presence of pre-TCR is sufficient to achieve a
down-regulation of the Fas molecule and protect cells from Fas-mediated apoptosis.
Apoptosis induced by DNA damage is p53-dependent in
thymocytes (24). In vivo, severe combined
immunodeficiency × p53-deficient mice are permissive for the
generation of DP thymocytes, and there seems to be a correlation
between inactivation of the p53 gene and progression to the DP stage
(43, 44). The N terminus of the p53 protein has been implicated in
recruitment of important p53 regulators such as Mdm2 and corepressors
(45). Indeed, phosphorylation of Ser15 causes dissociation
of p53 from Mdm2 (46) and allows for the association of coactivators of
its transcriptional activity (Ref. 45 and references therein). We show
here that N-terminal phosphoryation of p53 in response to DNA damage is
clearly defective in pT /TCR -expressing cells but not in cells
expressing only TCR or a tail-less form of pT b and
TCR . We may argue that, when either one isoform of the pT is
present, p53 is being constitutively inactivated, even in the presence
of double-stranded DNA breaks that in vivo are caused by
V(D)J recombination (24). If this were the case, targets of p53
transcriptional activation such as p21WAF and Bax proteins
would be reduced in pT -transfectants. In fact, as described in the
present study, expression of pT seems per se to be able
to down-regulate the amount of p21WAF and Bax in our
system. At the same time it up-regulates the amount of other apoptosis
regulators such as the pro-survival protein Bcl-2.
As reported, expression of Bcl-2 protein was low-to-moderate in double
negative cells and declined to negligible levels in DP cells, prior to
re-expression in positively selected single positive cells (47-50).
The decline in Bcl-2 expression as DN cells matured to DP cells was
evident in DN stage IV cells, which expressed significantly lower
levels than the preceding DN III cells. We believe the possibility that
Bcl-2 is the sole protein for rescue from different types of apoptotic
stimuli is somewhat unlikely based on in vivo data,
particularly for pre-TCR-mediated rescue. On the one hand Bcl-2
overexpression is not sufficient to prevent cell death in
pre-TCR-deficient T cells (26, 28). On the other hand, it is very
likely that p53 induces death via a Bcl-2-insensitive pathway, as
pointed out by Green and Schuler (51). First, p53 can trigger cell
death through Fas expression (52). Second, Fas-deficient × severe
combined immunodeficiency thymocytes can develop normally (42). Third,
Bcl-2 expression fails to block Fas-mediated apoptosis in the thymus
(53, 54). Also, the down-regulation of Fas indicates that pre-TCR
selection inhibits apoptosis by both Bcl-2-regulated and
Bcl-2-independent pathways. Given that -selection appears to involve
multiple regulators of apoptosis, it would seem unlikely that complete
rescue of pre-TCR deficiency could be achieved by regulation of a
single signaling cascade.
Proteins belonging to the stress-activated protein kinase and
mitogen-activated protein kinase families have long been known to play
a pivotal role in the development and differentiation of thymocytes
(38). In particular, the consequence of CD2-driven JNK activation in T
cells is inhibition of Fas expression and rescue of T cells from
apoptosis (55), similar to that shown in this study for the pre-TCR.
Interestingly, although both isoforms of pT trigger the activation
of cascades leading to the phosphorylation of c-Jun, only the short
form, pT b, is able transduce signals that activate p38,
a member of the mitogen-activated protein kinase family of proteins
essential for the transition from DN to DP cells. Is important to
mention here that expression of this short pT is enough in our
system to trigger p38 activation, even in the absence of any exogenous stimulation. Indeed, a p38 activity is induced in thymocytes without any apparent requirement of extracellular factors (56). The data
presented here that presence of a functional pre-TCR is enough to drive
p38 activation may provide a valuable explanation for the high p38
activity detected intrathymically. Although p38 is strictly required
for differentiation of immature thymocytes (39), constitutive
activation of the p38 pathway leads to excessive thymocyte
proliferation and impaired thymic development (40). In line with these
data, our results show that the presence of the long pT isoform is
enough to down-regulate p38 activity to levels below those of control
and TRC -expressing cells. These results allow us to argue that the
exquisite regulation of p38 activity that seems to be required for
normal T cell development in vivo might be achieved by the
selective expression of one specific pT isoform, a hypothesis that
will need to be challenged in vivo.
Based on the results obtained in this study, we propose that pre-TCR
may affect cell survival via effects on Fas and p53 in addition to the
reported regulation of NF- B and cell differentiation through the
control of mitogen-regulated kinases, all of which are regulated across
the -selection point. This proposal accommodates the possibility
that late DN thymocytes are vulnerable both to death by DNA damage
caused by V(D)J recombination events and to death induced via Fas-type
receptors. In fact, thymocytes from mice lacking functional Fas ligand
(gld) show normal sensitivity to apoptosis transduced by p53 (15), thus
demonstrating that Fas- and p53-mediated apoptosis are independent
processes in thymocytes. In p53-deficient mice, the survival defects
caused by pre-TCR absence were remarkably restored (26); thus p53
appears to be a very distal component of the pre-TCR pathway. This
pleiotropy of signals elicited by expression of a single receptor
complex may serve in vivo to block the various apoptotic
stimuli to which thymocytes are subjected during the -selection
checkpoint, thus ensuring the viability and growth of key cellular
populations and helping guarantee a successful thymic development.
 |
ACKNOWLEDGEMENTS |
Part of this work was performed at the
Department of Molecular, Cellular, and Developmental Biology of Yale
University (New Haven, CT) with the support of Dr. Adrian Hayday, who
is gratefully acknowledged. We are especially grateful to Dr. J. Silvio
Gutkind at the National Institutes of Health (Bethesda, MD) for help
and support.
 |
FOOTNOTES |
*
This work was supported in part by grants from the Spanish
Research Council and the Pharmacia Corporation to the Department of
Immunology and Oncology. We gratefully acknowledge the institutional support of the "Fundación Ramón Areces" to the Centro
de Biología Molecular and the help from Dr. Federico Mayor, Jr.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
This work is dedicated to the memory of the late Jesús Murga, Sr.
§
Recipients of grants by the Spanish Ministerio de
Ciencia y Tecnología (Ramón y Cajal Programme).
¶
To whom correspondence should be addressed: Centro de
Biología Molecular "Severo Ochoa," Universidad
Autónoma de Madrid, Campus de Cantoblanco, Madrid 28049, Spain.
E-mail: cmurga@cbm.uam.es.
Published, JBC Papers in Press, July 11, 2002, DOI 10.1074/jbc.M203553200
 |
ABBREVIATIONS |
The abbreviations used are:
TCR, T cell
receptor;
DN, double negative;
DP, double positive;
DAPI, 2-(4-amidinophenyl)-6-indolecarbamidine;
TUNEL, terminal
deoxinucleotidyltransferase-mediated dUTP-fluorescein isothiocyanate
nick end labeling;
JNK, c-Jun N-terminal kinase;
HA, hemagglutinin;
pT , pre-TCR chain;
FACS, fluorescence-activated cell
sorting.
 |
REFERENCES |
| 1.
|
Mombaerts, P.,
Clarke, A. R.,
Rudnicki, M. A.,
Iacomini, J.,
Itohara, S.,
Lafaille, J. J.,
Wang, L.,
Ichikawa, Y.,
Jaenisch, R.,
Hooper, M. L.,
and Tonegawa, S.
(1992)
Nature
360,
225-231[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Shinkai, Y.,
Koyasu, S.,
Nakayama, K.-I.,
Murphy, K. M.,
Loh, D. Y.,
Reinherz, E. L.,
and Alt, F. W.
(1993)
Science
259,
822-825[Abstract/Free Full Text]
|
| 3.
|
Mallick, C.,
Dudley, E. C.,
Viney, J. L.,
Owen, M. J.,
and Hayday, A. C.
(1993)
Cell
73,
513-519[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Fehling, H. J.,
Krotkova, A.,
Saint-Ruf, C.,
and von Boehmer, H.
(1995)
Nature
375,
795-798[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Xu, Y.,
Davidson, L.,
Alt, F. W.,
and Baltimore, D.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
2169-2174[Abstract/Free Full Text]
|
| 6.
|
Godfrey, D. I.,
Kennedy, J.,
Suda, T.,
and Zlotnik, A.
(1993)
J. Immunol.
150,
4244-4252[Abstract]
|
| 7.
|
Takahama, Y.,
and Singer, A.
(1992)
Science
258,
1456-1462[Abstract/Free Full Text]
|
| 8.
|
Saint-Ruf, C.,
Ungewiss, K.,
Groettrup, M.,
Bruno, L.,
Fehling, H. J.,
and von Boehmer, H.
(1994)
Science
266,
1208-1212[Abstract/Free Full Text]
|
| 9.
|
Berger, M. A.,
Dave, V.,
Rhodes, M. R.,
Bosma, G. C.,
Bosma, M. J.,
Kappes, D. J.,
and Wiest, D. L.
(1997)
J. Exp. Med.
186,
1461-1467[Abstract/Free Full Text]
|
| 10.
|
von Boehmer, H.,
and Fehling, H. J.
(1997)
Annu. Rev. Immunol.
15,
433-452[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Barber, D. F.,
Passoni, L.,
Wen, L.,
Geng, L.,
and Hayday, A. C.
(1998)
J. Immunol.
161,
11-16[Abstract/Free Full Text]
|
| 12.
|
Trop, S.,
Steff, A.-M.,
Denis, F.,
Wiest, D. L.,
and Hugo, P.
(1999)
Eur. J. Immunol.
7,
2187-2196
|
| 13.
|
Gibbons, D.,
Douglas, N. C.,
Barber, D. F.,
Liu, Q.,
Sullo, R.,
Geng, L.,
Fehling, H. J.,
von Boehmer, H.,
and Hayday, A. C.
(2001)
J. Exp. Med.
194,
695-703[Abstract/Free Full Text]
|
| 14.
|
Saint-Ruf, C.,
Panigada, M.,
Azogui, O.,
Debey, P.,
von Boehmer, H.,
and Grassi, F.
(2000)
Nature
406,
521-527
|
| 15.
|
O'Connor, L. O.,
Harris, A. W.,
and Strasser, A.
(2000)
Cancer Res.
60,
1217-1220[Abstract/Free Full Text]
|
| 16.
|
Sunder-Plassmann, R.,
and Reinherz, E. L.
(1998)
J. Biol. Chem.
273,
24249-24257[Abstract/Free Full Text]
|
| 17.
|
Aifantis, I.,
Borowski, C.,
Gounari, F.,
Lacorazza, H. D.,
Nikolich-Zugich, J.,
and von Boehmer, H.
(2002)
Nat. Immunol.
3,
483-488[Medline]
[Order article via Infotrieve]
|
| 18.
|
Dudley, E. C.,
Girardi, M.,
Owen, M. J.,
and Hayday, A. C.
(1995)
Curr. Biol.
5,
659-669[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Hoffman, E. S.,
Passoni, L.,
Crompton, T.,
Leu, T.,
Schatz, D.,
Koff, A.,
Owen, M. J.,
and Hayday, A. C.
(1996)
Genes Dev.
10,
948-962[Abstract/Free Full Text]
|
| 20.
|
von Boehmer, H.,
Aifantis, I.,
Azogui, O.,
Feinberg, J.,
Saint-Ruf, C.,
Zober, C.,
Garcia, C.,
and Buer, J.
(1998)
Immunol. Rev.
165,
111-119[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Aifantis, I.,
Azogui, O.,
Feinberg, J.,
Saint-Ruf, C.,
Buer, J.,
and von Boehmer, H.
(1998)
Immunity
9,
649-655[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Ogasawara, J.,
Watanabe-Fukunage, R.,
Adachi, M.,
Matsuzawa, A.,
Kasugai, T.,
Kitamura, Y.,
Itoh, N.,
Suda, T.,
and Nagata, S.
(1993)
Nature
364,
806-809[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Voll, R. E.,
Jimi, E.,
Phillips, R. J.,
Barber, D. F.,
Rincon, M.,
Hayday, A. C.,
Flavell, R. A.,
and Ghosh, S.
(2000)
Immunity
13,
677-689[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Guidos, C. J.,
Williams, C. J.,
Grandal, I.,
Knowles, G.,
Huang, M. T. F.,
and Danska, J. S.
(1996)
Genes Dev.
10,
2038-2054[Abstract/Free Full Text]
|
| 25.
|
Fotedar, R.,
Brickner, H.,
Saadatmandi, N.,
Rousselle, T.,
Diederich, L.,
Munshi, A.,
Jung, B.,
Reed, J. C.,
and Fotedar, A.
(1999)
Oncogene
18,
3652-3658[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Haks, M. C.,
Krimpenfort, P.,
van den Brakel, J. H. N.,
and Kruisbeek, A. M.
(1999)
Immunity
11,
91-101[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Washburn, T.,
Schweighoffer, E.,
Gridley, T.,
Chang, D.,
Fowlkes, B. J.,
Cado, D.,
and Robey, E.
(1997)
Cell
88,
833-843[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Maraskovsky, E.,
O'Reilly, L. A.,
Teepe, M.,
Corcoran, L. M.,
Peschon, J. J.,
and Strasser, A.
(1997)
Cell
89,
1011-1019[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Groettrup, M.,
Ungewiss, K,
Azogui, O.,
Palacios, R.,
Owen, M. J.,
Hayday, A. C.,
and von Boehmner, H.
(1993)
Cell
75,
283-294[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Murga, C.,
Laguinge, L.,
Wetzker, R.,
Cuadrado, A.,
and Gutkind, J. S.
(1998)
J. Biol. Chem.
273,
19080-19080[Abstract/Free Full Text]
|
| 31.
|
Aragane, Y.,
Kulms, D.,
Metze, D.,
Wilkes, G.,
Poppelmann, B.,
Luger, T. A.,
and Schwarz, T.
(1998)
J. Cell. Biol.
140,
171-182[Abstract/Free Full Text]
|
| 32.
|
Rehemtulla, A.,
Hamilton, C. A.,
Chinnaiyan, A. M.,
and Dixit, V. M.
(1997)
J. Biol. Chem.
272,
25783-25786[Abstract/Free Full Text]
|
| 33.
|
Sheikh, M. S.,
Antinore, M. J.,
Huang, Y.,
and Fornace, A. J., Jr.
(1998)
Oncogene
17,
2555-2563[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Kraus-Berthier, L.,
Jan, M.,
Guilbaud, N.,
Naze, M.,
Pierre, A.,
and Atassi, G.
(2000)
Clin. Cancer Res.
6,
297-304[Abstract/Free Full Text]
|
| 35.
|
el-Deiry, W. S.,
Tokino, T.,
Velculescu, V. E.,
Levy, D. B.,
Parsons, R.,
Trent, J. M.,
Lin, D.,
Mercer, W. E.,
Kinzler, K. W.,
and Vogelstein, B.
(1993)
Cell
75,
817-825[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Miyashita, T.,
and Reed, J. C.
(1995)
Cell
80,
293-299[CrossRef][Medline]
[Order article via Infotrieve]
|
| 37.
|
Siciliano, J. D.,
Canman, C. E.,
Taya, Y.,
Sakaguchi, K.,
Apella, E.,
and Kastan, M. B.
(1997)
Genes Dev.
11,
3471-3481[Abstract/Free Full Text]
|
| 38.
|
Rincon, M.,
Flavell, R. A.,
and Davis, R. J.
(2001)
Oncogene
20,
2490-2497[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Mulroy, T.,
and Sen, J.
(2001)
Eur. J. Immunol.
31,
3056-3063[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Diehl, N. L.,
Enslen, H.,
Fortner, K. A.,
Merritt, C.,
Stetson, N.,
Charland, C.,
Flavell, R. A.,
Davis, R. J.,
and Rincon, M.
(2000)
J. Exp. Med.
191,
321-334[Abstract/Free Full Text]
|
| 41.
|
Hayday, A. C.,
Barber, D. F.,
Douglas, N. C.,
and Hoffman, E. S.
(1999)
Semin. Immunol.
11,
239-249[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Yasutomo, K.,
Maeda, K.-I.,
Hisaeda, H.,
Good, R. A.,
Kuroda, Y.,
and Himeno, K.
(1997)
J. Immunol.
158,
4729-4733[Abstract]
|
| 43.
|
Bogue, M. A.,
Zhu, C.,
Aguilar-Cordova,
Donehower, L. A.,
and Roth, D. B.
(1996)
Genes Dev.
10,
553-565[Abstract/Free Full Text]
|
| 44.
|
Nacht, M.,
Strasser, A.,
Chan, Y. R.,
Harris, A. W.,
Schlissel, M.,
Bronson, R. T.,
and Jacks, T.
(1996)
Genes Dev.
10,
2055-2066[Abstract/Free Full Text]
|
| 45.
|
Wahl, G. M.,
and Carr, A. M.
(2001)
Nat. Cell Biol.
3,
E277-E285[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Shieh, S. Y.,
Ikeda, M.,
Taya, Y.,
and Prywes, C.
(1997)
Cell
91,
325-334[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Gratiot-Deans, J.,
Ding, L.,
Turka, L. A.,
and Nunez, G.
(1993)
J. Immunol.
151,
83-91[Abstract]
|
| 48.
|
Veis, D. J.,
Sentman, C. L.,
Bach, E. A.,
and Korsmyer, S. J.
(1993)
J. Immunol.
151,
2546-2554[Abstract]
|
| 49.
|
Andjelic, S.,
Jain, N.,
and Nikolic-Zugic, J.
(1993)
J. Exp. Med.
178,
1745-1751[Abstract/Free Full Text]
|
| 50.
|
Tao, W.,
The, S.-J.,
Melhado, I.,
Jirik, F.,
Korsmeyer, S.,
and Teh, H.-S.
(1994)
J. Exp. Med.
179,
145-153[Abstract/Free Full Text]
|
| 51.
|
Green, D. R.,
and Schuler, M.
(2000)
Nat. Immunol.
1,
15-17[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Owen-Schaub, L. B.,
Zhang, W.,
Cusack, J. C.,
Angelo, L. S.,
Santee, S. M.,
Fujiwara, T.,
Roth, J. A.,
Deisseroth, A. B.,
Zhang, W.-W.,
Kruzel, E.,
and Radinsky, R.
(1995)
Mol. Cell. Biol.
15,
3032-3040[Abstract]
|
| 53.
|
Strasser, A.,
Harris, A. W.,
Huang, D. C. S.,
Krammer, P. H.,
and Cory, S.
(1995)
EMBO J.
14,
6136-6147[Medline]
[Order article via Infotrieve]
|
| 54.
|
Huang, D. C. S.,
Hahne, M.,
Schroeter, M.,
Frei, K.,
Fontana, A.,
Villunger, A.,
Newton, K.,
Tschopp, J.,
and Strasser, A.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
14871-14876[Abstract/Free Full Text]
|
| 55.
|
Ayroldi, E.,
Migliorati, G.,
Cannarile, L.,
Moraca, R.,
Delfino, D. V.,
and Riccardi, C.
(1997)
Blood
89,
3717-3726[Medline]
[Order article via Infotrieve]
|
| 56.
|
Sen, J.,
Kapeller, R.,
Fragoso, R.,
Sen, R.,
Zon, L. I.,
and Burakoff, S. J.
(1996)
J. Immunol.
156,
4535-4538[Abstract]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Mandal, K. M. Crusio, F. Meng, S. Liu, M. Kinsella, M. R. Clark, O. Takeuchi, and I. Aifantis
Regulation of lymphocyte progenitor survival by the proapoptotic activities of Bim and Bid
PNAS,
December 30, 2008;
105(52):
20840 - 20845.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Schito, O. N. Demidov, S. Saito, J. D. Ashwell, and E. Appella
Wip1 Phosphatase-Deficient Mice Exhibit Defective T Cell Maturation Due To Sustained p53 Activation.
J. Immunol.,
April 15, 2006;
176(8):
4818 - 4825.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Mandal, C. Borowski, T. Palomero, A. A. Ferrando, P. Oberdoerffer, F. Meng, A. Ruiz-Vela, M. Ciofani, J.-C. Zuniga-Pflucker, I. Screpanti, et al.
The BCL2A1 gene as a pre-T cell receptor-induced regulator of thymocyte survival
J. Exp. Med.,
February 22, 2005;
201(4):
603 - 614.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Kim, J. M. White, A. S. Shaw, and B. P. Sleckman
MAPK p38{alpha} Is Dispensable for Lymphocyte Development and Proliferation
J. Immunol.,
February 1, 2005;
174(3):
1239 - 1244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. Stanic, J. S. Bezbradica, J.-J. Park, N. Matsuki, A. L. Mora, L. Van Kaer, M. R. Boothby, and S. Joyce
NF-{kappa}B Controls Cell Fate Specification, Survival, and Molecular Differentiation of Immunoregulatory Natural T Lymphocytes
J. Immunol.,
February 15, 2004;
172(4):
2265 - 2273.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|